# DESCRIPTION

## FIELD

- introduce ligand for cancer cell targeting

## BACKGROUND

- motivate cancer treatment
- describe chemotherapy limitations
- introduce targeting therapy
- describe antibody-drug conjugates
- discuss folate receptors
- describe glutamine transporters
- explain cancer cell glucose uptake
- discuss ASCT2 transporter
- introduce PET probes
- discuss limitations of current targeting therapy
- motivate glutamine as novel ligand

## SUMMARY

### Technical Problem

- describe diversity of cancer
- describe non-uniformity of cancer
- discuss adverse side effects
- motivate need for novel ligand
- describe limitations of antibody-drug conjugates
- discuss glutamine as novel ligand
- describe limitations of glutamine as ligand
- motivate multivalent binding

### Solution to Problem

- introduce multivalent ligand
- describe ligand structure
- describe polymer main chain
- describe polypeptide main chain
- describe linker structure
- describe protective group
- describe detectable label or anticancer drug
- describe composition and method of use

### Advantageous Effects of Invention

- describe advantages of invention

## DESCRIPTION OF EMBODIMENTS

- define ligand
- introduce glutamine transporter
- describe multivalent binding
- explain uptake into cell
- discuss stereostructure of groups
- specify number of groups
- introduce polymer main chain
- describe linking of groups to polymer main chain
- specify polymer main chain examples
- describe primary or secondary amino group
- introduce polypeptide as polymer main chain
- specify number average molecular weight
- introduce polypeptide with lysines
- describe linking of groups to polypeptide
- specify linker examples
- introduce α-polylysine as polymer main chain
- describe linking of groups to α-polylysine
- specify preferred linking
- introduce polymer micelle
- describe block copolymer
- specify hydrophilic segment examples
- specify hydrophobic segment examples
- list block copolymer examples
- describe linking of groups to hydrophilic segment
- specify linker examples
- discuss micelle formation
- specify hydrophilic segment structure
- specify hydrophobic segment structure
- describe block copolymer structure
- conclude ligand structure
- define detectable label
- examples of detectable labels
- examples of fluorescent labels
- examples of luminescent labels
- examples of contrast agents
- examples of metal atoms and compounds
- examples of radioisotopes and compounds
- examples of nanoparticles and liposomes
- linking detectable label to ligand
- linking anticancer drug to ligand
- examples of anticancer drugs
- capping group for pH-dependent elimination
- examples of capping groups
- formula for ligand
- definition of pharmaceutically acceptable salt
- examples of pharmaceutically acceptable salts
- production of ligand
- condensation reaction
- deprotection conditions
- formation of polymer micelle
- method for forming polymer micelle
- composition of the present invention
- composition for diagnosing or detecting cancer
- composition for treating cancer
- administration route
- dosage selection
- definition of subject
- method for diagnosing or detecting cancer
- ligand for diagnosing or detecting cancer
- use of ligand in medicament manufacture
- method for treating cancer

### EXAMPLES

- list reagents
- list cell types and animals
- list measuring instruments and analytical software
- define abbreviations
- introduce Cy5-P[Lys(G1n)]n compounds
- introduce Cy5-P[Lys(α-Glu)]n compounds
- describe synthesis of Cy5-P[Lys(G1n)]n (n=25, 46, 106)
- synthesize compound (b) (n=25, 46, 106)
- synthesize compound (c) (n=25, 46, 106)
- synthesize compound (d) (n=25, 46, 106)
- synthesize compound (e) (n=25, 46, 106)
- characterize compound (e) (n=25)
- characterize compound (e) (n=46)
- characterize compound (e) (n=106)
- synthesize Cy5-P[Lys(G1n)]n (n=25, 46, 106)
- describe synthesis of Cy5-P[Lys(α-Glu)]n (n=46, 106)
- synthesize compound (f) (n=46)
- synthesize compound (f) (n=106)
- synthesize Cy5-P[Lys(α-Glu)]n (n=46, 106)
- introduce examples
- synthesize acetal-PEG-NH2
- deprotect acetal groups
- react with Cy5-NH2 and reducing agent
- prepare Cy5-PEG-Ac
- evaluate uptake of compounds
- incubate Bx-PC3 cells with compounds
- measure intracellular fluorescence intensity
- show changes in uptake over time
- discuss uptake results
- evaluate uptake for different cell types
- incubate Bx-PC3, HepG2, and HUVEC cells with compounds
- measure intracellular fluorescence intensity
- show uptake results for different cell types
- discuss uptake results for different cell types
- evaluate changes in uptake with inhibitor
- incubate cells with inhibitor and compounds
- measure intracellular fluorescence intensity
- show changes in uptake with inhibitor
- discuss uptake results with inhibitor
- evaluate inhibition of polymer ligand uptake by anti-ASCT2 antibody
- incubate cells with antibody and compounds
- measure intracellular fluorescence intensity
- show inhibition results
- discuss inhibition results
- evaluate changes in uptake at low temperature
- incubate cells with compounds at low temperature
- measure intracellular fluorescence intensity
- show changes in uptake at low temperature
- discuss uptake results at low temperature
- evaluate uptake of ligands with different polymerization degrees
- incubate cells with ligands of different polymerization degrees
- measure intracellular fluorescence intensity
- show uptake results for different polymerization degrees

## INDUSTRIAL APPLICABILITY

- application of ligand

